Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 27 for “"Secukinumab"”.
-
The development of a liposomal form Secukinumab – an IL 17 pathway inhibitor in the treatment of psoriasis
… shown great efficacy with fewer side effects, is Secukinumab. Secukinumab is an anti-IL17 antibody that works by stopping the action of IL17, a cytokine that is known to have a major role in the pathogenesis of psoriasis. This work is based on the development of a new way to commence drug therapy …
-
The development of a liposomal form Secukinumab – an IL 17 pathway inhibitor in the treatment of psoriasis
… shown great efficacy with fewer side effects, is Secukinumab. Secukinumab is an anti-IL17 antibody that works by stopping the action of IL17, a cytokine that is known to have a major role in the pathogenesis of psoriasis. This work is based on the development of a new way to commence drug therapy …
-
Molecular Regulatory Modulations in Axial Spondylarthritis: Effect of IL-17 Blockade and The Role of CD4+ T Cells
… biologics that target IL-17A, such as secukinumab, have demonstrated improved clinical outcomes for axSpA patient pain and inflammation. Despite this translational success, there is a gap in understanding why some axSpA patients do not respond to IL-17A-blocking therapy or why Tregs are …
-
Μελέτη πολυμορφισμών ανοσορυθμιστικών κυτοκινών σε ασθενείς με ψωρίαση και άλλες δερματολογικές παθήσεις
… with treatment response to apremilast and secukinumab and evaluate their predictive value in therapeutic outcomes. Specifically, this study aims to investigate the impact of genetic polymorphisms on psoriasis patients treated with apremilast or secukinumab while simultaneously assessing …
-
Διερεύνηση ανοσολογικών δεικτών στην ψωριασική αρθρίτιδα
… effect of biological therapy and specifically secukinumab on the development of antigen-specific ANA. Material and Methods: Depending on the primary and secondary aims of the study, up to 203 patients with psoriatic disease including 89 patients with PsA and 114 patients with psoriasis were …
-
Κατανόηση της εξατομικευμένης ανοσοπαθογένειας της διαπυητικής ιδρωταδενίτιδας: έμφαση στη σεκουκινουμάμπη
… The impact of addition of patient plasma and of secukinumab was investigated. Results: Patients were classified into four strata based on pus levels of tumour necrosis factor-alpha (TNFα) and of activation of interleukin (IL)-1; high-TNF/low-IL-1 (30.9%), low-TNF/low-IL-1 (27.3%), …
-
Διερεύνηση της βέλτιστης θεραπευτικής προσέγγισης ανάμεσα στους αντι-TNFα, αντι-ΙL12/23, αντι-IL17 και αντι-IL23 βιολογικούς παράγοντες και την απρεμιλάστη σε ασθενείς με ψωρίαση σε δύσκολες-προς-αντιμετώπιση περιοχές και προσδιορισμός πιθανών προγνωστικών παραγόντων θεραπευτικής έκβασης
… brodalumab, guselkumab, risankizumab, secukinumab, ustekinumab, adalimumab, infliximab, etanercept, certolizumab pegol or apremilast. The efficacy and safety of the respective treatments overall in psoriasis, and by anatomical region, were evaluated at weeks 16, 24, 52, 62 and 78. …
-
Διερεύνηση πιθανής ενθεσοπάθειας σε ασθενείς με ψωρίαση συγκεκριμένων εντοπίσεων, με σύγχρονες απεικονιστικές μεθόδους (High resolution MRI ή/και Ultrasound), πριν και μετά την αγωγή με βιολογικούς παράγοντες ή απρεμιλάστη
… start of medication with biological therapy " secukinumab" or apremilast. With the help of imaging techniques, the course and progress of the patients under treatment was monitored at 0 and 16 weeks. Method: The study included 76 patients of all ages who were followed at the outpatient clinics …
-
Identifying Candidate Biomarkers of Clinical Response to Ustekinumab in Psoriasis
… use of biologic drugs, including ustekinumab, secukinumab, adalimumab and newer anti-interleukin (IL)-23p19 biologics, have revolutionised treatment for the immune-mediated inflammatory skin disease, psoriasis. Ustekinumab targets the shared IL-12/IL-23p40 subunit, while anti-IL-23p19 biologics …
-
Einfluss von IL-17 auf die Stabilität und Funktion von regulatorischen T-Zellen
… Reaktion der Zellen auf IL 17, anti IL 17 und Secukinumab sowie ein Th 17 induzierendes Milieu im Vergleich von PSO und HC zu evaluieren. In der Analyse der PBMCs von PSO und HC konnten bei PSO tendenziell weniger inflammatorische Marker, wahrscheinlich aufgrund der niedrigen …
-
Der Einfluss von Th17-stimulierenden, Interleukin-17 und Interleukin-17-inhibierenden Faktoren auf in vitro Funktion und Phänotyp regulatorischer T-Zellen bei gesunden Probanden und Patienten mit Juveniler Idiopathischer Arthritis
… FoxP3-Expression insbesondere in JIA-Tregs. Secukinumab bewirkte eine Anpassung der FoxP3-Expression der Tregs in der Patientengruppe auf etwa das Niveau der gesunden Kontrollen. Insgesamt bestätigt diese Arbeit eine proinflammatorische Dysbalance bei JIA-Patienten mit Shift zu Th17-like …
-
Methylierungsmuster des FOXP3-Gens von regulatorischen T-Zellen bei Patienten mit Autoimmunkrankheiten am Beispiel von Psoriasis und Psoriasis-Arthritis
… Zellgemisch oder dem IL-17A-Inhibitor Secukinumab kultiviert. Im Anschluss wurde die isolierte DNA mit Bisulfit behandelt und mittels Pyrosequenzierung der Methylierungsgrad am Enhancer, Promotor und an der TSDR des FOXP3-Gens bestimmt. Außerdem wurde bei fünf Patienten exemplarisch die …
-
HIDRADENITIS SUPPURATIVA WITH 20 OR MORE DRAINING TUNNELS: A NATION-WIDE RETROSPECTIVE STUDY.
… 12 received anti-IL17 agents, including secukinumab (9) and bimekizumab (3), and 9 were also offered off-label treatment options, including guselkumab (4), infliximab (3), risankizumab (1) and ustekinumab (1). At univariate regression analysis, gluteal involvement was a negative predictor …
-
Investigation of novel CD1a-lipid antigen presentation pathways in the skin
… phototherapy or the anti-IL-17A biologic therapy secukinumab), atopic dermatitis and healthy controls. The findings were integrated with public datasets and were validated using imaging mass cytometry at the protein level. These data, alongside clinical and scientific knowledge of the disease, …
-
Sympathetic Signaling Alters T-Lymphocyte Differentiation and Function Through Beta Adrenergic Mechanisms
… IL-17A, IL-17A neutralizing antibodies, such as secukinumab and ixekizumab, have been developed and show promise in attenuating IL-17A-related diseases. However, these neutralizing antibodies only dampen IL-17A signaling already in circulation as opposed to decreasing the amount of protein …
-
Sympathetic Signaling Alters T-Lymphocyte Differentiation and Function Through Beta Adrenergic Mechanisms
… IL-17A, IL-17A neutralizing antibodies, such as secukinumab and ixekizumab, have been developed and show promise in attenuating IL-17A-related diseases. However, these neutralizing antibodies only dampen IL-17A signaling already in circulation as opposed to decreasing the amount of protein …
-
Sympathetic Signaling Alters T-Lymphocyte Differentiation and Function Through Beta Adrenergic Mechanisms
… IL-17A, IL-17A neutralizing antibodies, such as secukinumab and ixekizumab, have been developed and show promise in attenuating IL-17A-related diseases. However, these neutralizing antibodies only dampen IL-17A signaling already in circulation as opposed to decreasing the amount of protein …
-
Sympathetic Signaling Alters T-Lymphocyte Differentiation and Function Through Beta Adrenergic Mechanisms
… IL-17A, IL-17A neutralizing antibodies, such as secukinumab and ixekizumab, have been developed and show promise in attenuating IL-17A-related diseases. However, these neutralizing antibodies only dampen IL-17A signaling already in circulation as opposed to decreasing the amount of protein …
-
Sympathetic Signaling Alters T-Lymphocyte Differentiation and Function Through Beta Adrenergic Mechanisms
… IL-17A, IL-17A neutralizing antibodies, such as secukinumab and ixekizumab, have been developed and show promise in attenuating IL-17A-related diseases. However, these neutralizing antibodies only dampen IL-17A signaling already in circulation as opposed to decreasing the amount of protein …
-
Sympathetic Signaling Alters T-Lymphocyte Differentiation and Function Through Beta Adrenergic Mechanisms
… IL-17A, IL-17A neutralizing antibodies, such as secukinumab and ixekizumab, have been developed and show promise in attenuating IL-17A-related diseases. However, these neutralizing antibodies only dampen IL-17A signaling already in circulation as opposed to decreasing the amount of protein …
Page 1 of 2